Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif., September 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.
YahooyesterdayEW
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
Yahoo3 days agoEW
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.
Yahoo3 days agoEW
Edwards Lifesciences (EW): The Medical Device Leader Behind the TAVR Boom
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
Yahoo7 days agoEW
Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences
Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on
Benzinga8 days agoEW
MDT's Q1 Earnings on Deck: How Should You Play the Stock Now?
Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.
Yahoo9 days agoEW
Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?
Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...
Yahoo14 days agoEW
Should You Hold Edwards Lifesciences Stock in Your Portfolio?
EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
Yahoo15 days agoEW
Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings
Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...
Yahoo15 days agoEW
Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a market capitalization
Benzinga16 days agoEW
Putting Patients at the Heart of Innovation: Voices Across Asia Pacific Help Shape the Future of Structural Heart Care
As structural heart disease continues to impact a growing number of people across Asia Pacific amid a rapidly ageing population, Edwards Lifesciences (Edwards) brought together patients for its annual Asia-Pacific Patient Experience event. The programme created a platform for patients, caregivers, healthcare professionals and employees to share perspectives, foster meaningful connections and deepen understanding of the patient journey.
Yahoo16 days agoEW
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga21 days agoEW
$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalization
Benzinga22 days agoEW
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation
Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
Yahoo22 days agoEW
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?
Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.
Yahoo23 days agoEW
Edwards Lifesciences: Strong Execution, But Little Room For Error At $90
SeekingAlpha23 days agoEW
Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else
Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.
SeekingAlpha23 days agoEW
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
Yahoo29 days agoEW
Aristotle Value Equity WM Q2 2026 Portfolio Performance
For the second quarter of 2026, Aristotle Capitalâs Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Read more here.
SeekingAlpha29 days agoEW
Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Yahoolast monthEW